FDA Rejects Moderna's mRNA Flu Vaccine Application Amidst Scrutiny
WASHINGTON, D.C. - The Food and Drug Administration (FDA) rejected Moderna's application for its new mRNA-based flu vaccine, citing issues with the clinical trial design, according to multiple news sources. This decision, which surprised Moderna, comes amid increased scrutiny of vaccine approvals and a challenging flu season.
The FDA's rejection of the vaccine application was announced by Moderna. The agency cited problems with the trial design and the comparator vaccine used, according to reports. This development occurs as less than half of adults are getting flu shots this year, according to Vox.
The rejection also comes as the FDA faces increased scrutiny. One FDA official stated that COVID-19 vaccine mandates are no longer legally possible for healthy individuals, according to Fox News. The news of the rejection comes as the world is making progress toward a universal flu vaccine, according to Vox.
In other news, multiple sources reported growing challenges in managing urban groundwater supplies, primarily due to climate change. Coverage encompasses various aspects of water resources, including access, environmental treaties, and conflict impacts, alongside conservation efforts and scientific advancements, according to Nature News.
Discussion
AI Experts & Community
Be the first to comment